MACH7 TECHNOLOGIES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.715 AUD | -3.38% |
|
+8.33% | -9.49% |
| Apr. 24 | Mach7 Technologies Posts 20% Annual Recurring Revenue Increase to AU$22.3 Million for March Quarter | MT |
| Apr. 24 | Transcript : Mach7 Technologies Limited, Q3 2024 Earnings Call, Apr 24, 2024 |
| Sales 2024 * | 30.02M 19.61M | Sales 2025 * | 39.07M 25.52M | Capitalization | 172M 113M |
|---|---|---|---|---|---|
| Net income 2024 * | -7M -4.57M | Net income 2025 * | -1M -653K | EV / Sales 2024 * | 4.94 x |
| Net cash position 2024 * | 24.1M 15.74M | Net cash position 2025 * | 28.67M 18.72M | EV / Sales 2025 * | 3.68 x |
| P/E ratio 2024 * |
-24.6
x | P/E ratio 2025 * |
-89.3
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 73.21% |
More Fundamentals
* Assessed data
More news
Latest transcript on Mach7 Technologies Limited
| 1 day | -3.38% | ||
| 1 week | +8.33% | ||
| 1 month | +3.62% | ||
| 3 months | +5.15% | ||
| 6 months | +8.33% | ||
| Current year | -9.49% |
1 week
0.65
0.75
1 month
0.640.75
Current year
0.640.79
1 year
0.520.99
3 years
0.451.26
5 years
0.251.59
10 years
0.111.59
| Managers | Title | Age | Since |
|---|---|---|---|
Ravi Krishnan
FOU | Founder | - | 06-12-31 |
Michael Lampron
CEO | Chief Executive Officer | - | - |
Dyan O’Herne
DFI | Director of Finance/CFO | - | 22-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Eliot Siegel
BRD | Director/Board Member | - | 18-08-02 |
Michael Lampron
CEO | Chief Executive Officer | - | - |
Robert Bazzani
CHM | Chairman | - | 19-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 0.715 | -3.38% | 132,020 |
| 24-04-24 | 0.74 | +5.71% | 871,083 |
| 24-04-23 | 0.7 | +3.70% | 135,557 |
| 24-04-22 | 0.675 | +2.27% | 143,786 |
| 24-04-19 | 0.66 | 0.00% | 199,560 |
Delayed Quote Australian S.E., April 26, 2024 at 01:59 am EDT
More quotes
Mach7 Technologies Limited is an Australia-based medical imaging systems provider. The principal activity of the Company is the development and commercialization of medical imaging and data management software solutions for global healthcare enterprises. The core of these offerings is the Mach7 Enterprise Imaging Solution, encompassing Enterprise Data Management, Enterprise Diagnostic Viewing and Departmental Workflow applications. Mach7âs Enterprise Data Management solution consists of a Vendor Neutral Archive (VNA) and data administration tools, which allow for the fast storage, access, retrieval and viewing of images across a healthcare network with connectivity to the cloud. Enterprise Diagnostic Viewing offers healthcare professionals consolidated access to all patient images and data, ensuring clinical staff have timely access to the right information to diagnose and treat patients. It offers its solutions across North America, Asia Pacific, and the Middle East region.
Calendar
2024-08-27
- Q4 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
0.715
AUD
Average target price
1.241
AUD
Spread / Average Target
+73.59%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -9.49% | 112M | |
| -5.77% | 14.68B | |
| -40.71% | 2.71B | |
| -12.92% | 2.44B | |
| -8.78% | 1.51B | |
| -.--% | 1.12B | |
| +40.66% | 518M | |
| +91.79% | 502M | |
| +11.68% | 239M | |
| +1.67% | 183M |
- Stock Market
- Equities
- M7T Stock
